Qualigen Therapeutics (NASDAQ:AIXC) & AngioSoma (OTCMKTS:SOAN) Financial Analysis

Qualigen Therapeutics (NASDAQ:AIXC) and AngioSoma (OTCMKTS:SOAN) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Qualigen Therapeutics and AngioSoma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1	0	0	0	1.00
AngioSoma	0	0	0	0	0.00

Given AngioSoma’s higher probable upside, analysts plainly believe AngioSoma is more favorable than Qualigen Therapeutics.

Volatility & Risk

Qualigen Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, AngioSoma has a beta of -0.46, suggesting that its stock price is 146% less volatile than the S&P 500.

Earnings & Valuation

This table compares Qualigen Therapeutics and AngioSoma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97 million	($6.47)	-0.23
AngioSoma	N/A	N/A	-$540,000.00	N/A	N/A

Insider and Institutional Ownership

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of AngioSoma shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Qualigen Therapeutics and AngioSoma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
AngioSoma	N/A	N/A	-1,245.34%

Summary

Qualigen Therapeutics beats AngioSoma on 5 of the 8 factors compared between the two stocks.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

About AngioSoma

AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.